Cell Therapies

Cell Therapies

Cell therapy products have the potential to treat a variety of cancers and other diseases. Whether you’re developing an allogeneic or autologous product, an adoptive cell therapy (such as CAR T, NK or DC) or a stem cell-derived product, you’ll benefit from our expert teams’ deep knowledge and experience.

Assess safety, establish proof of concept and feasibility to support IND/IMPD/CTA submissions, and rapidly transition to first-in-human trials

In vitro and in vivo pharmacology disease models

Advanced therapy development solutions

Discovery Solutions

Preclinical Solutions

  • In vitro & in vivo toxicology/safety/tumorigenicity
  • In vivo range finding
  • Combined pharmacology/toxicology
  • Surgical transplantation procedures
  • MRI/Stereotaxic guided administration
  • Bioanalysis/PK: persistence
  • Biomarkers: strategy, assay development & testing
  • Regulatory & strategic product development consulting
  • Clinical development preparation & planning
  • BioCMC testing & analytical control strategy– safety, identity, strength & purity
  • Commercialization strategy

New cell and gene therapy suite

A macro investment in micro science

Cell and gene therapies are incredibly intricate, but they’re making a huge difference in the drug development market and in the lives of patients. Learn all about our $9.2 million investment in cell and gene therapy.

MAKING YOUR BREAKTHROUGHS POSSIBLE

Our major commitment to your early development studies

Over the past five years, we’ve invested more than $700 million in nonclinical development to enhance our capabilities for your programs. From expanded lab space in our U.S., European and Asia Pacific sites to state-of-the-art instrumentation and digitized workflows, we’ve innovated where it matters most to empower your healthcare mission.

SparC of Innovation magazine

Let's Start the Conversation

Want to learn more?

Contact Us